776 PATENT ABSTRACTS

copper (II). The L-lysyl-glycyl-L-histidine and salt thereof have a fibroblast proliferation promoting activity and then it is useful as a wound healing agent.

5591718

N E U T R O P H I L A C T I V A T I N G

F A C T O R S

Walz Alfred Koeniz, SWITZERLAND

The invention relates to a novel factor comprising a polypeptide denominated ENA-78, said factor being derived from epithelial cells and having the ability to activate neutrophils, as well as DNA coding for such factors, methods of treating neutrophil deficiencies, methods of identifying inhibitors of ENA-78 using a novel assay, the inhibitors identified by such an assay, and methods for treating acute and chronic lung disorders using such inhibitors.

5 5 9 1 7 1 9

M E T H O D F O R T R E A T I N G

A C U T E A N D C H R O N I C

I N F L A M M A T O R Y D I S O R D E R S

U S I N G P O L Y P E P T I D E S W I T H

F I B R O N E C T I N A C T I V I T Y

Furcht Leo; McCarthy James B; Wahl Sharon M; Allen Janice Minneapolis, MN, UNITED STATES Assigned to Regents of the University of Minnesota; The United States of America as represented by the Secretary of Health and Human Services

A method for treating acute or chronic inflammatory or autoimmune disorders using polypeptides with fibronectin or related activity is provided. The method involves (administering an amount of) one or more polypeptides corresponding to isolated amino acid residue sequences of the 33 kD carboxy terminal heparin-binding region located on the A chain of fibronectin to effectively suppress inflammation and impairment of tissue function in a patient.

5593622

P R E P A R A T I O N O F L I P O S O M E S

W I T H P E G - B O U N D

P H O S P H O L I P I D O N S U R F A C E

Yoshioka Hirosh; Goto Hiroshi Shizuoka ken, JAPAN Assigned to Terumo Kabushiki Kaisha

Agents for inhibiting adsorption of proteins on the liposome surface and liposomes which are agglutination-free by binding said inhibiting agent on the surface are disclosed. The above-mentioned inhibiting agents comprise a hydrophobic moiety and a hydrophilic macromolecular chain moiety. Adsorption of plasma proteins on the liposomes is inhibited due to the hydrophilic moiety exposed on the liposome surface with a result that agglutination of the liposomes in plasma is prevented. Therefore, there is no danger of embolism in blood vessels inhibiting blood flow when the liposomes are introduced into the living body. Accordingly, the liposomes are especially highly useful as artificial erythrocytes for which a large dose of liposomes is needed for administration. Moreover, when liposomes are introduced into the living body, antibody protein (immunoglobulin) to the liposome which is an antigen will be adsorbed on the liposome to produce foreign body recognition in the phagocytes (macro-phage) with a result that the liposome will be included in the macrophage and disappear within a short period of time. Thus, inhibition of the protein adsorption on liposome can delay disappearance of the liposome in plasma. In addition, a method for preparing the above-described liposomes is disclosed.

5 5 9 3 6 5 6

M E T A L - B I N D I N G T A R G E T E D

P O L Y P E P T I D E C O N S T R U C T S

Belinka Benjamin A; Coughlin Daniel; Alvarez Vernon; Wood Richard Kendall Park, NJ, UNITED STATES Assigned to Cytogen Corporation

This invention relates to the preparation and use of novel open-chain or cyclic polypeptide constructs in which two or more polypeptide chains, in an open-chain constluct, or one or more

PATENT ABSTRACTS 777

chains, in a cyclic construct,are chemically derivatized such that the resulting construct exhibits both metal-binding capability and tissue-, organ- or cell-targeting selectivity. In particular, the polypeptide constructs of the present invention comprise compounds of the formula (I): (*See Patent for Chemical Structure*) (I) in which, B is a hydrocarbon backbone, P is a polypeptide capable of targeting particular cells, tissues or organs of the body, A may be the group -NR'-NR"- or the group -NR'-NR"-L- in which L may be an aliphatic or aromatic linker group, R, R', and R" may be the same or different and may be hydrogen or an aliphatic group, m is an integer> or =2, provided that the groups R, R', R", L and P of a given chain may be the same or different from the groups R, R', R", L and P of another chain, n is an integer> or =0; or a pharmaceutically acceptable salt thereof. The constructs of the present invention are capable of binding a variety of metallic species.

5593676

M E T H O D OF KILLING B CELLS USING ANTIBODIES W H I C H

BIND CD1M

Bhat Neelima M; Bieber Marcia M; Teng Nelson N H Cupertino, CA, UNITED STATES Assigned to The Leland Stanford Junior University

Methods are provided for inducing cell death in B-cells, including neoplastic B-cells, by employing reagents that bind to a B-cell epitope. Particularly, antibodies specific for the marker can be administered to a host to induce death in B-cells to which the antibodies bind or can be used in ex vivo clinical situations to selectively remove B-oells. A B-cell specific oligosaccharide epitope useful as a B-cell marker has been identified. The ligand being recognized on B iymphocytes has no apparent similarities to any of the known pan-B ceils markers. In addition, proteins which specifically bind the disclosed epitope are provided. Human monoclonal antibody 216, which recognizes this B-cell epitope, is cytotoxic to B-cells and binds all CD19+ and CD20+ B lymphocytes in human peripheral blood and spleen. Furthermore, MAb 216 does not distinguish B cells by the isotype expressed, binding IgG+ and IgM+ cells with equal intensity, and also bind all B cells regardless

of their CD5 expression. Methods to inhibit neoplastic B-cell growth by administering a B-eell-cytotoxic protein are presented. These products and methods find use in diagnosis and therapy.

5593678

PROTECTION OF TELEOST FISH

Evans Donald L; Jaso-Friedmann Lilian Athens, GA, UNITED STATES Assigned to University of Georgia Research Foundation

Utility of protein phosphatase inhibitors to protect teleost fish from microorganismic pathogens is disclosed. The present invention provides pharmaceutical compositions, kits, and methods of therapeutic and prophylactic treatments comprising sodium orthovanadate or vanadate-mimetic protein phosphatase inhibitors to protect fish, for example, catfish, from infection and disease caused by micreorganismic pathogens, e.g., Edwardsiella. Sodium orthovanadate, a protein phosphatase inhibitor, and vanadate-mimetic protein phosphatase inhibitors activate in vitro and in vivo the cytotoxicity of teleost nonspecific cytotoxic cells (NCC).

5593822

IGG DEPLETED SERUM PREPARATIONS AND

METHODS FOR ANTIBODY PRODUCTION

Zeng Qing S; Irie Reiko F Alhambra, CA, UNITED STATES Assigned to John Wayne Cancer Institute

A method for preparing serum depleted of IgG to be used in the production of lgG monoclonal antibodies is disclosed. Animal serum is contacted with protein G or protein A prior to addition to base media to obtain a superior cell culture medium depleted of serum derived IgG antibodies. Included in the disclosure are improved media preparations for cell culture of antibody producing cells and incorporating the antibody depleted serum and improved methods of producing the antibodies.